Inhibition of this pathway by LY294002 effectively neutralized the tumor‐promoting effects of SPAG4, highlighting its potential as a therapeutic target in CRC metabolic reprogramming [139]. This evidence concerns the gene SPAG4 and colorectal carcinoma.